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Abstract
Using 13C NMR, we tested the hypothesis that protection by preconditioning is associated with reduced glycogenolysis
during ischemia. Preconditioned rat hearts showed improved postischemic function and reduced ischemic damage relative to
ischemic controls after 30 min stop-flow ischemia and 30 min reperfusion (contractility: 30 þ 10 vs. 2 þ 2%; creatine kinase
release: 41 þ 4 vs. 83 þ 15 U/g; both P6 0.05). Preconditioning decreased preischemic [13C]glycogen by 24% (a 10% decrease
in total glycogen), and delayed ischemic [13C]glycogen consumption by 5^10 min, reducing ischemic glycogenolysis without
changing acidosis relative to controls. Upon reperfusion, glycogen synthesis resumed only after preconditioning. Glutamate
13C-isotopomer analysis showed recovery of Krebs cycle activity with higher anaplerosis than before ischemia (23 þ 4 vs.
11 þ 3%, P6 0.05), but in controls reperfusion failed to restore flux. Compared to control, preconditioning before 20 min
ischemia increased contractility (86 þ 10 vs. 29 þ 14%, P6 0.05) and restored preischemic anaplerosis (13 þ 3 vs. 39 þ 9%,
P6 0.05). Preconditioning is associated with reduced glycogenolysis early during ischemia. However, protection does not
rely on major variations in intracellular pH, as proposed earlier. Our isotopomer data suggest that preconditioning
accelerates metabolic and functional recovery during reperfusion by more efficient/active replenishment of the depleted
Krebs cycle. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
Ischemic preconditioning makes use of a mild
stress (brief periods of ischemia) to activate endoge-
nous myocardial defense mechanisms, and thus pro-
vides protection against a further major stress, such
as persistent ischemic injury [1]. The adenosine, bra-
dykinin, and norepinephrine released during precon-
ditioning ischemia may trigger protection by stimu-
lating protein kinase C, provided that the threshold
activity of the enzyme is exceeded [2]. The kinase
then phosphorylates target proteins, including ATP-
sensitive potassium channels [3] ; alternatively, it may
modulate the key-regulating enzymes of carbohy-
drate metabolism [4].
Many studies have attempted to relate the bene¢-
cial e¡ects of preconditioning to glucose metabolism
[5^7], on the basis of some reports indicating that
contractile activity is directly related to glycolytic
ATP synthesis. Goto et al. [8] have shown that tran-
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sient interruption of glucose uptake or glucose me-
tabolism may somehow activate protein kinase C
and thus trigger the preconditioned state. King and
Opie [9] have reported that severe glycogen depletion
after long-term acetate perfusion cancels the precon-
ditioning e¡ect.
The relationship between glycolysis/glycogenolysis
and ischemic damage is still highly controversial.
Although glycolysis supports cell function by means
of the anaerobic production of ATP, the accumula-
tion of glycolytic end-products (lactate, sugar and
triose phosphates, and protons originating from
ATP hydrolysis) is thought to determine the extent
of ischemic cell damage; we have recently reviewed
this controversial role of glycolysis in precondition-
ing [10]. In the global ischemic model, precondition-
ing has been associated with a decrease in glycolytic
£ux. Wolfe et al. [5] and de Albuquerque et al. [6]
assumed that the bene¢cial e¡ects of preconditioning
are related to the reduction in lactate accumulation
and proton production caused by lower glycolytic
rates, despite reduced ATP production. The glycogen
hypothesis states that reduced preischemic glycogen
in preconditioned hearts is protective insofar as it
reduces glycolytic catabolite accumulation during
subsequent prolonged ischemia. Weiss et al. [4]
have indicated that depressed glycogenolysis may
be responsible for the protective e¡ect; however,
others have observed no relationship between func-
tional recovery after prolonged ischemia and pre-
ischemic glycogen levels [11] or glycogen depletion
during ischemia [9].
Our study concentrated on the relationship be-
tween ischemic preconditioning and glycogen metab-
olism. The use of a protocol that does not induce any
signi¢cant di¡erence in intracellular pH between the
preconditioned hearts and ischemic controls through-
out the experiment [12] allowed us to exclude that
major variations in acidity are implicated in the pro-
tective e¡ect. The e⁄cacy of preconditioning protec-
tion was evaluated by monitoring cytosolic enzyme
release and functional recovery. Release of cytosolic
enzymes is a marker of the e¡ect of preconditioning
on irreversible damage (infarction). Improved func-
tional recovery in preconditioned hearts can be due
to less infarction and/or less stunning. Most likely,
reduced contractile dysfunctioning in preconditioned
hearts re£ects reduced infarct size since ischemic pre-
conditioning does not protect against stunning [13].
On the other hand preconditioning may attenuate
arrhythmias [14], but our model produces little
ECG disturbances. We focused on the rate of glyco-
gen synthesis and degradation in hearts perfused
with [1-13C]glucose. Analysis of glutamate isotopom-
ers [15] made it possible to measure carbon entry into
the Krebs cycle and the relative activity of anapler-
otic and oxidative reactions, a ¢eld that has so far
hardly been explored in preconditioning protocols.
The obtained data suggest that preconditioning pro-
tects by an easier replenishment of the depleted
Krebs cycle metabolites through anaplerosis. Fur-
thermore, preconditioning is associated with a reduc-
tion in glycogenolysis early during ischemia.
2. Materials and methods
2.1. Heart perfusion
Fed male Sprague-Dawley rats (250^300 g) were
stunned and bled. The heart was rapidly isolated
and arrested in ice-cold perfusion £uid. The aorta
was cannulated and the heart was Langendor¡-per-
fused at a constant pressure of 70 mmHg for 20 min
in order to allow coronary £ow to be measured. This
value (9^11 ml/min) was applied to the subsequent
constant £ow perfusion period. The perfusion me-
dium was a modi¢ed Krebs-Henseleit solution (com-
position in mM): NaCl 137; KCl 5.4; MgCl2 1.2;
CaCl2 1.8; NaH2PO4 0.46; NaHCO3 12; K-D-glu-
cose 5.5 (or 99% enriched [1-13C]glucose, Cambridge
Isotope Laboratories), with 10 U/l insulin and satu-
rated at 37‡C with O2/CO2 (95%:5%), pH 7.4. To
minimize temperature changes during ischemia, the
hearts were immersed in 37‡C perfusate, controlled
by a Bruker temperature controller accessory. To
monitor contractility a balloon connected to a Stat-
ham pressure transducer was inserted into the left
ventricle. The balloon was ¢lled to give an end-dia-
stolic pressure of 4^8 mmHg. Total ischemia was
obtained by cross-clamping the perfusion line. The
left ventricular balloon was collapsed during ische-
mia and re¢lled after a few minutes of reperfusion to
assess recovery of contractile function. No ¢brilla-
tion phenomena were observed during our experi-
ments.
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2.2. 31P and 13C NMR spectroscopy
The hearts were inserted into a broad-band 20-mm
probe of a Bruker AMX 500 wide-bore NMR spec-
trometer operating at 11.74 T. Field homogeneity
was optimized by shimming the water proton signal
using the decoupling coil. 31P NMR spectra were
obtained at 202.4 MHz with a 60‡ pulse of 20 Ws,
and a 2-s delay using blocks of 60^90^150 transients
corresponding to 2^3^5 min of accumulation.
We previously [12,16] have described measure-
ments of myocardial phosphorus metabolites, pH,
[Mg2] and phosphorylation potential in detail.
Brie£y, peak areas of phosphocreatine (PCr), L-
ATP and inorganic phosphate (Pi), corrected for sat-
uration by comparison with spectra obtained in fully
relaxed conditions, were converted to intracellular
concentrations by calibration against a capillary in-
serted close to the organ in the NMR tube and con-
taining Na-methylenediphosphonate (100 mM). In-
tracellular pH was derived from the chemical shift
of Pi relative to PCr (N) using the equation
pH = 6.773log(N35.78)/(3.273N). Zero ppm was as-
signed to PCr. The validity of this equation has been
checked for our experimental condition [17]. The
phosphorylation potential, PP = [ATP]/([ADP]c[Pi]),
was estimated from the creatine-kinase equation:
ATP=ADPcPi  fPCr=CrcPigcH=Kck
1
where [H] is the cytosolic H concentration and Kck
is the pH- and [Mg2]-dependent creatine-kinase
equilibrium constant. The following relationship
was used to calculate [H]/Kck, according to Bunger
et al. [18]:
logH=Kck  7:5230:97pH 3:12Mg20:11 2
The creatine concentration [Cr] was determined ac-
cording to Bunger et al. [18] and the creatine pool
(PCr+Cr) was checked to remain constant during
each experiment. The cytosolic free [Mg2] was de-
termined as described in [19,20] by means of the
following equation:
Mg2  KDcfN KL3N 0K L =N
0 0
KL3N
0
K L 31g 3
in which KD is the dissociation constant of ATP, and
NKL, NPKL, and NQKL, respectively, represent the chem-
ical-shift di¡erences between K-P and L-P resonances
of ATP in the heart and in solutions with and with-
out saturating Mg2. The pH dependence of the
chemical shifts of ATP and MgATP was taken into
account by ¢tting Mosher’s [20] experimental data to
biparametric equations. KD was 50 mM [19] and
corrected for pH dependence and [K] dependence.
Free [Mg2] was 0.44 þ 0.06 before prolonged ische-
mia, it triplicated during the ischemia in precondi-
tioned and control hearts, but returned to basal val-
ue only in PCI hearts on reperfusion.
1H-Decoupled 13C-spectra were obtained at 125.72
MHz using the MLEV-16 sequence. Free induction
decays were collected in 2K data points and zero-
¢lled to 8K, using blocks of 100^150^250 transients
corresponding to 2^3^5 min of accumulation time.
The pulse width was 23 Ws (60‡) and the recycling
time 1.1 s. A line broadening of 25 Hz was intro-
duced before Fourier transformation. The chemical
shifts are reported in relation to tetramethylsilane,
using L-C1 glucose at 97 ppm as the internal
reference standard. A capillary tube ¢lled with a so-
lution containing 100 mM [2-13C]ribose (99% en-
riched, Cambridge Isotope Laboratories) was used
as the external standard. Metabolite concentrations
were measured by integrating the areas under the
individual peaks. Corrections for the nuclear Over-
hauser e¡ect and partial saturation e¡ects were per-
formed.
NMR spectra of the extracts were obtained using a
5-mm inverse probe: (a) 1H (500.14 MHz): presatu-
ration of water, 90‡ pulse (11 Ws), 2 s presaturation
delay and 31 Hz line broadening; (b) 13C (202.46
MHz): 45‡ pulse (5.5 Ws), 2 s delay and 1 Hz line
broadening and 1H-decoupling (MLEV-16); (c) 31P
(125.77 MHz): 60‡ pulse (8 Ws), 2 s delay and 1 Hz
line broadening.
2.3. Tissue extracts
At the times indicated in the experimental protocol
by arrows (Fig. 1, set 2), the hearts were freeze-
clamped using Wollenberger clamps cooled in liquid
N2. The tissues were stored at 380‡C, extracted us-
ing 3.6% cold perchloric acid, neutralized to pH 7
with KOH, freeze-dried and redissolved in 0.6 ml
deuterated water for NMR analysis.
BBADIS 61974 24-10-00
S. Bradamante et al. / Biochimica et Biophysica Acta 1502 (2000) 363^379 365
2.4. Experimental protocol
The protocols of the two sets of experiments (1
and 2) are shown in Fig. 1. The hearts were ran-
domly assigned to either the preconditioned (PCI)
or the ischemic (I) group. Set 1, which was used
for high-energy phosphate metabolism (n = 16) and
glycogen NMR analysis (n = 12), consisted of: 42
min stabilization, 30 min stop-£ow ischemia and
30 min reperfusion (I) or 30 min stabilization, four
cycles of 2 min ischemia and 3 min reperfusion,
30 min stop-£ow ischemia and 30 min reperfusion
(PCI). The di¡erent stabilization periods were chosen
to ensure that both groups received the same quan-
tity of labeled glucose before the long ischemia: since
the PCI organs were reperfused with labeled glucose
during preconditioning, the I group was given la-
beled glucose for an additional 12 min.
Set 2 was used for isotopomer analysis. The hearts
(n = 25) were extracted after (A) 30 min stabilization
(normoxic hearts); (B) 30 min ischemia (ischemic
hearts); (C) 30 min ischemia^30 min reperfusion (is-
chemic-reperfused hearts); (D) preconditioning^30
min ischemia (preconditioned-ischemic hearts); (E)
preconditioning^30 min ischemia^30 min reperfusion
(preconditioned-ischemic-reperfused hearts). In anal-
ogy with set 1, in cases B and C, the stabilization
period was 42 min; in cases D and E, it was 30 min.
In cases C and E, [1-13C]glucose was only used dur-
ing reperfusion in order to characterize Krebs cycle
activity during this period without any labeling con-
tamination due to the preceding part of the protocol.
Protocols C and E were repeated with a shorter is-
chemic period (20 min, n = 8) and indicated as I20
and PCI20, respectively.
In both sets of experiments, the di¡erent stabiliza-
tion periods had no signi¢cant e¡ects on all the mea-
sured parameters.
The hearts were weighed at the end of the experi-
ment, and their glycogen content, expressed as
Wmoles of glucose residue per gram wet weight, was
determined.
2.5. 13C Isotopomer analysis
Isotopomer analysis of the glutamate signals
present in the 13C NMR spectra of the hearts ex-
tracted at selected time-points of the protocol (set
2) was used to evaluate the 13C-enrichment of the
acetyl-CoA pool. This approach provides indications
concerning Krebs cycle activity over di¡erent peri-
ods. However, in the globally ischemic groups (B
and D), the 13C-spectra of glutamate re£ect the entry
of acetyl-CoA only during the ¢rst few minutes of
global ischemia when some oxygen is still present. As
the hearts did not always reach metabolic and iso-
topic steady state at the selected time-points, either
steady state or non-steady state analysis was used
depending on the experimental conditions. As Weiss
et al. [21] have shown the complete labeling of glu-
tamate after 30 min of perfusion, we used the steady-
state analysis in cases A, C, E, I20 and PCI20 of
protocol set 2; in the other cases (B and D), the
Fig. 1. Diagram of the protocol used in this study in which per-
fusion with [1-13C]glucose started at the time-points indicated
with asterisk. Set 1: after 30 min stabilization, the precondi-
tioned hearts (PCI) underwent four cycles of 2 min stop-£ow is-
chemia and 3 min reperfusion; the control ischemic hearts (I)
had a no-intervention period of 42 min. Both PCI and I hearts
subsequently underwent 30 min of stop-£ow ischemia and 30
min of reperfusion. Set 2: the hearts were freeze-clamped at the
indicated time points (s).
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non-steady state approach was applied. Fig. 2 shows
a representative spectrum of a heart extract. Steady-
state analysis uses the input of all of the multiplet
components of glutamate carbons C2, C3 and C4,
thus providing a complete description of the labeling
pattern in the acetyl-CoA pool, including a measure
of the relative £ux through the anaplerotic pathways.
Of the three variables (the fractional enrichment of
acetyl-CoA, anaplerotic vs. oxidative £ux, and the
fractional enrichment of the anaplerotic pool), the
last is likely to be the least accurate. We applied
the method illustrated by Malloy et al. [15]. The rel-
ative intensities of the multiplets attributed to gluta-
mate carbons C2, C3, and C4 were evaluated by
integration and deconvolution procedures. The three
variables (Fc2, the fractional enrichment of acetyl-
CoA; y, anaplerotic vs. oxidative £ux; Fa1, the frac-
tional enrichment of the anaplerotic pool) were de-
termined by means of the analytical solution of the
following relevant equations relating the biochemical
information to the relative concentration of groups
of isotopomers:
Fractional enrichment
C3F  yF a1  F c2=2y 1 4
C4F  F c2 5
Multiplets
C2S  2y 1232F c2y 13F c2  F2c2=2y 12
6
C2D23  F c22 2y3F c2=2y 12 7
C3S  F c0y F c0=y 1 8
C3D  13F c0y F c0=y 13F2c2=y 1 9
C4D34  yFa1  F c2=2y 1 10
with Ci i = 2,3,4, carbon in position i in glutamate;
Ci F, fraction of the carbon in position i that is 13C;
CiS, area of singlet/total multiplet Ci area; C2D23,
area of doublet (C-2, C-3)/total multiplet C2 area;
C4D34, area of doublet (C-3, C-4)/total multiplet C4
area; Fc0 and Fa0, fraction of acetyl-CoA pool and
anaplerotic pool, respectively, that is unlabeled,
Boundary conditions: 1sFc2s 0; Fc0+Fc2 = 1,
ys 0, 1sFa1s 0; Fa0+Fa1 = 1.
We used the TCA-SIM spectra simulation com-
puter program [15] and compared experimental and
simulated spectra to validate our analysis. Non-
steady state analysis has been presented by Malloy
et al. [22] ; it is based on information derived from
the analysis of the glutamate C4 multiplets plus the
ratio of enrichment in glutamate C3 and C4. It pro-
vides a measure of the contribution of 13C-enriched
glucose and unlabelled sources to acetyl-CoA. This
approach does not allow the evaluation of other con-
tributions. Both methods do not require the measure-
ment of oxygen consumption.
2.6. Estimates of Krebs cycle £ux by 13C NMR
spectroscopy
We estimated Krebs cycle £ux by using the ap-
proach proposed by Weiss et al. [21] and validated
by Cohen and Bergman [23]. The Weiss method is
based on the following hypothesis. (1) The increasing
labeling of Krebs-cycle metabolic intermediates can
serve as a ‘lap counter’ for the 13C Krebs cycle £ux.
(2) Krebs cycle £ux is inversely proportional to the
time di¡erence between the labeling (half-maximum
enrichment) of C4 and C2 (or C3) of glutamate, since
these positions are enriched in subsequent ‘turns’ of
the Krebs cycle.
On this basis, it is possible to estimate the KT
parameter, which relates to total Krebs cycle £ux
using Eq. 11. KT can be calculated from the sum of
13C NMR-detected metabolites, the fractional enrich-
ment of acetyl-CoA, and vt50 de¢ned as the di¡er-
ence between the t50 (time to half-maximal enrich-
ment) of glutamate C4 and that of C2:
KT  4 13C NMR detected metabolites Wmol=g=
F c2v t50 min 11
The 13C NMR-detected metabolites are essentially
glutamate and aspartate in the glucose perfused heart
representing 96^97% of the combined glutamate, as-
partate and citrate pools. The fractional enrichment
of acetyl-CoA is Fc2 and vt50 is derived by the label-
ing kinetic of glutamate isotopomers. This analysis
assumes that the intermediate pool sizes are stable
during enrichment. It is known that changes in the
smaller Krebs cycle intermediate pools (oxaloacetate,
fumarate etc) can occur during ischemia, but they
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have little impact on the glutamate enrichment and
on KT [21].
To evaluate total Krebs cycle £ux (XTCA) we used
the following two relations (Eqs. 12 and 13) pro-
posed by Cohen and Bergman [23] that have been
proved to take into account di¡erences in relative
anaplerosis.
KT  0:7682 XTCA0:0783
valid for 10% anaplerosis 12
KT  0:8250 XTCA0:3159
valid for 30% anaplerosis 13
2.7. Biochemical analysis
Total myocardial glycogen was measured enzy-
matically in freeze-clamped hearts [24]. The coronary
e¥uent at the end of stabilization and during 30 min
of reperfusion was sampled, and creatine kinase
(CK) and lactate dehydrogenase (LDH) release was
measured in both groups as an index of cell integrity.
Enzyme activity was assayed at 37‡C using an auto-
analyzer [25,26].
2.8. Statistical analysis
The data are expressed as mean þ standard error
(S.E.M.). Analysis of variance and Student’s t-test
were used for evaluating their statistical signi¢cance.
Signi¢cance was considered at the P6 0.05 level.
3. Results
3.1. Contractile and metabolic function
Figs. 3^5 show the e¡ect of the preconditioning
protocol adopted in this study. During precondition-
ing, ischemia induced a decrease in the rate-pressure
product to 5%, which recovered toV80% of baseline
values upon 3 min reperfusion (Fig. 3). Heart rate
showed smaller variations. After long stop-£ow is-
chemia in both groups, only the PCI hearts resumed
their contractile force upon reperfusion (30 þ 10% of
Fig. 2. A representative 13C NMR spectrum of tissue extract from ischemic heart perfused for 42 min with [1-13C]glucose. The abbre-
viations denote labeled glutamate multiplets (C2, C3, C4), and lactate (L) and alanine (A) methyl peaks.
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baseline rateUpressure product and 71 þ 13% of
heart rate, P6 0.05 and P6 0.001 vs. I, respectively).
As previously found [16], there were minor di¡er-
ences in high-energy phosphate content between PCI
and I hearts. Brie£y, before ischemia, precondition-
ing did not signi¢cantly vary ATP, Pi or intracellular
pH, but reduced phosphocreatine (PCr) and phos-
phorylation potential (PP) by 28% and 39% respec-
tively (P6 0.05 vs. baseline, Figs. 4 and 5). These
data indicate that PCI hearts are balanced at a lower
metabolic level than ischemic controls. During long
ischemia and upon reperfusion, the phosphates, pH
and phosphorylation potential behaved similarly in
both groups; only PCr was higher in the PCI group
later during reperfusion. This is in line with many
reports showing that high-energy phosphate content
does not correlate with functional recovery in ische-
mic and preconditioned hearts. We could not mea-
sure pH from 13C-spectra as reported by Chacko and
Weiss [27] due to our lower insulin level and shorter
period of labeled perfusion: in our experimental con-
ditions, the labeled C3 of glycerol 3-phosphate was
hardly detectable.
Tissue necrosis was evaluated by the measurement
of CK and LDH release. Fig. 6 summarizes time-
dependent enzyme release. The PCI and I groups
showed similarly low levels of CK and LDH release
during the stabilization period but, after 30 min is-
chemia, the release from the PCI hearts was much
lower than that from the I hearts (P6 0.05). The
cumulative release of CK was 41 þ 4 (PCI) vs.
83 þ 15 U/g wet weight (I, P6 0.05).
Fig. 4. Changes in ATP, PCr and Pi during 30 min of stop-
£ow ischemia and 30 min reperfusion in ischemic (I, n = 8, R)
and preconditioned hearts (PCI, n = 8, a). Basal values:
PCr = 4.75 þ 0.34; ATP = 2.93 þ 0.21; Pi = 2.21 þ 0.15 Wmol/g wet
wt. Mean þ S.E.M.
Fig. 3. Changes in function during protocol set 1: heart rate
(HR) basal value = 210 þ 26 beats/min; rateUpressure product
(RPP) basal value = 43 000 þ 7360 mmHg/min. The precondi-
tioned hearts (PCI, n = 14, a) recovered better than the ische-
mic controls (I, n = 14, R). t = 0 represents the onset of 30 min
stop-£ow ischemia. PC, preconditioning. Mean þ S.E.M.
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3.2. Glycogen synthesis and degradation
Insulin perfusion induced a marked increase in to-
tal glycogen with the concurrent incorporation of
labeled glucose residues, as monitored in the 13C-
spectra by the growth of the signal at 100.6 ppm
shown in Fig. 7. Fig. 8 shows glycogen synthesis
and breakdown in the PCI and I groups, as detected
using the NMR approach throughout protocol set 1.
The apparent accumulation rate of labeled glycogen
was almost linear for 20 min, and then decreased
towards a plateau. This led to a net synthesis of
5.1 þ 0.6 Wmol/g [1-13C]glycogen during 30 min stabi-
lization, with an average net synthesis rate of
0.17 þ 0.05 Wmol/min, which is in good agreement
with the published data [28]. This value of accumu-
lated [13C]glycogen agrees with our biochemical de-
termination of total glycogen. The glycogen levels in
four control hearts (10.0 þ 0.1 Wmol/g) frozen imme-
diately after excision were compared with those of
four other hearts (17.2 þ 0.6 Wmol/g) in which glyco-
gen was determined after 30 min of glucose plus in-
sulin perfusion (P6 0.01 vs. controls). Since the PCI
organs were reperfused with labeled glucose during
Fig. 7. Representative 13C NMR spectrum acquired from a
perfused rat heart under preischemic conditions after 30 min of
labeled perfusion. The abbreviations denote [1-13C]glycogen
(G), the K- and L-anomers of [1-13C]glucose (K and L), and
[2-13C]ribose (R) used as standard.
Fig. 6. Irreversible damage, measured as the release of lactate
dehydrogenase (LDH) and creatine kinase (CK) into 1-min
samples of the coronary e¥uent, was less in the preconditioned
hearts (PCI, n = 4, a) than in the ischemic controls (I, n = 4,
R). Mean þ S.E.M.
Fig. 5. Changes in pH and phosphorylation potential during 30
min of stop-£ow ischemia and 30 min reperfusion in ischemic
and preconditioned hearts. For other details, see legend to Fig.
4.
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preconditioning, in order to ensure that both groups
received the same quantity before the long ischemia,
the I group was given labeled glucose for an addi-
tional 12 min. The longer infusion did not change
signi¢cantly the glycogen levels.
Preconditioning induced a 24% decrease in
[13C]glycogen (1.6 Wmol/g), in agreement with a
parallel, independent biochemical determination
(1.8 Wmol/g) made on a separate group of four hearts
frozen after preconditioning (total glycogen
15.4 þ 0.4 Wmol/g, P6 0.05 vs. pre-preconditioning
value). The NMR experiments indicated that this
decrease took place mainly during the ¢rst cycle of
ischemia and reperfusion (5 min), whereas almost no
net change in labeled glycogen content seemed to
occur thereafter. The plateau shown in Fig. 8 was
obtained by averaging the values obtained in each
cycle, since there was no synchronism of glycogen
synthesis and depletion with the short periods of is-
chemia and reperfusion.
During the ¢rst 5^8 min of the long ischemic peri-
od, the PCI hearts did not use [13C]glycogen, and so
its consumption was reduced by 23% (P6 0.05 vs. I),
with a depletion rate over the ¢rst 15 min of ischemia
of 0.30 þ 0.04 (PCI) vs. 0.42 þ 0.03 (I) Wmol/min
per g.
During 30 min ischemia, the glycogen pool was
severely depleted in both groups. Parallel biochemi-
cal determinations indicated that total glycogen in
the PCI hearts after ischemia (2.8 þ 0.7 Wmol/g) was
greater than that in the I group (1.0 þ 0.2 Wmol/g;
P6 0.05).
Upon reperfusion, only the PCI hearts recovered
metabolic and functional activity, showing an aver-
age postischemic labeling rate of glycogen of
0.04 þ 0.01 Wmol/min per g wet weight. The I hearts
did not resume any measurable glycogen synthesis.
3.3. Fractional enrichment and £ux in preconditioned
heart
In the normoxic group (set 2: A), 13C-enrichment
in the methyl carbon of acetyl-CoA was 43% (Table
1), the same value as the 13C-enrichment in the ala-
nine methyl carbon (from the 1H-spectra of the same
extracts). The preischemic anaplerotic £ux was 11%,
in line with published data [4,15,29]. Unlabelled en-
dogenous substrates signi¢cantly contributed to oxi-
dative £ux in both the PCI and I groups during the
¢rst few minutes of ischemia (set 2: B and D).
After 30 min reperfusion (set 2: E), the enrichment
of acetyl-CoA in PCI hearts was less (35%) than it
was initially (set 2: A, 43%), with the anaplerotic £ux
contributing 23% of the oxidative £ux needed to
maintain TCA cycle activity. Moreover, V80% of
the anaplerotic £ux originated from the glycolytic
substrate.
We estimated Krebs cycle £ux (XTCA) in the nor-
moxic (set 2: A) and preconditioned-ischemic-reper-
fused (set 2: E) cases by using the approach de-
scribed in Section 2. Fig. 10 shows the time course
of 13C-enrichment of the glutamate C4 and C2 iso-
topomers from a representative normoxic and pre-
conditioned postischemic heart. Glutamate C4 en-
richment precedes that of glutamate C2, and
maximal enrichment of both positions occurs within
W10^20 min (Fig. 10A) under normal perfusion.
Glutamate enrichment in the preconditioned posti-
schemic hearts (Fig. 10B) di¡ers from the normoxic
group: (1) lower levels of enrichment of both [4-13C]-
Fig. 8. 13C-Labeling and mobilization of [1-13C]glycogen during
protocol set I in preconditioned hearts (PCI, n = 6, a) and is-
chemic controls (I, n = 6, R). The labeled perfusion started at
t =350 min for the preconditioned hearts and t =342 min for
the controls. During the ¢rst 30 min of perfusion (stabilization),
the behavior of the two groups was almost identical. [1-13C]-
Glycogen was partially reduced by the ¢rst cycle of precondi-
tioning ischemia and was not further reduced by subsequent
cycles. In the PCI group, preischemic glycogen proved to be
lower than that in Group I, with reduced [1-13C]glycogen mobi-
lization during early ischemia (t = 0^15 min). Only the PCI
group resumed glycogen synthesis. Mean þ S.E.M.
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and [2-13C]glutamate are present in the postischemic
hearts; (2) the time of glutamate enrichment is faster
and the vt50 smaller. Table 2 shows the overall re-
sults of the analysis: in the preconditioned postische-
mic myocardium, the labeled glutamate pool is re-
duced by a factor of 3 and the Krebs cycle £ux
(KT and XTCA) is signi¢cantly increased relative to
the preischemic normoxic conditions. This can be
also seen from the di¡erent values of vt50 : higher
value re£ects slower Krebs cycle £ux.
We failed to obtain any interpretable result from
ischemic reperfused hearts (set 2: C) due to the in-
coherent labeling of glutamate probably caused by
the presence of focal areas of non-viable cells. This
inconvenience indicated that control hearts were irre-
versibly damaged after 30 min of stop-£ow ischemia.
To obtain evidence of the e¡ect of PC on reperfu-
sion, we performed separate experiments with a
shorter period of ischemia. Two groups of hearts
were subjected to 20 min stop-£ow ischemia and
30 min reperfusion where one group (PCI20) was
Fig. 9. Changes in function of hearts submitted to 20 min stop-
£ow ischemia. The preconditioned hearts (PCI, n = 4, a) recov-
ered better than the ischemic controls (I, n = 4, R). t = 0 repre-
sents the onset of 20 min stop-£ow ischemia. PC, precondition-
ing. Mean þ S.E.M.
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subjected to the preconditioning protocol of four
cycles of 2 min ischemia and 3 min reperfusion.
Both groups received [1-13C]glucose only during re-
perfusion. Due to the shorter ischemia, both groups
recovered function (Fig. 9), although at signi¢cantly
di¡erent extent (RPP: 86 þ 10 vs. 29 þ 14%,
P6 0.05). The results shown in Table 1 indicate
that both groups show comparable preischemic val-
ues for percent labeling of acetyl-CoA, lactate and
alanine concentrations. Instead, postischemic anaple-
rosis was signi¢cantly higher in the ischemic controls
(I20) than in the preconditioned hearts (39 þ 9 vs.
13 þ 3%, P6 0.05). Table 2 shows the results of the
analysis of TCA cycle £ux: in the postischemic my-
ocardium, the labeled glutamate pool was slightly
reduced in both groups while the Krebs cycle £ux
(KT and XTCA) was signi¢cantly increased in I20
(P6 0.05 vs. PCI20, set 2: A).
3.4. Alanine and lactate
Table 1 shows total lactate and alanine concentra-
tions and their percentage 13C-enrichment, measured
at the same selected time points of the protocol (set
2). Both metabolites showed a marked increase after
30 min ischemia, and recovered almost to the initial
value after 30 min reperfusion. The amounts found
in PCI and I hearts were not signi¢cantly di¡erent.
Because total ischemia leads to the rapid inhibition
of oxidative metabolism and negligible pyruvate con-
centrations in tissue, we could derive the mean gly-
colytic rate from alanine and lactate production dur-
ing ischemia [4]. During the ¢rst 15 min ischemia, the
mean glycolytic rate from the labeled substrate for-
mation due to labeled glucose consumption, was sig-
ni¢cantly reduced in PCI hearts (0.32 þ 0.03 vs.
0.58 þ 0.05 Wmol/min per g wet weight, P6 0.05). If
one consider the whole 30-min ischemic period, the
mean glycolytic rate derived from the formation of
total alanine and lactate was not signi¢cantly di¡er-
ent in the PCI and I groups (0.72 þ 0.2 vs. 0.96 þ 0.13
Wmol/min per g wet weight).
Fig. 10. Plot of time course of 13C-enrichment of glutamate C4
(E) and C2 (F) for a representative normoxic heart (A) and
that of another preconditioned and reperfused after 30 min
stop-£ow ischemia (B). The x-axis represents time of perfusion
with [1-13C]glucose. vt50 is the di¡erence between the times of
half-maximal enrichment for each isotopomer indicated by the
dotted line. The reperfused heart has lower glutamate levels
and shorter vt50 compared to the normoxic heart.
Table 2
13C NMR data and calculated Krebs cycle £ux parameters
Variable Normoxic (set 2: A) PC postischemic (set 2: E) I20 postischemic PCI20 postischemic
Glutamate vt50 (min) 11.5 þ 0.51 2.5 þ 0.3 3.5 þ 0.42 9.5 þ 0.5
[4-13C]Glutamate (Wmol (g wet wt.)31) 3.0 þ 0.31 1.0 þ 0.2 2.3 þ 0.2 2.4 þ 0.2
[3-13C]Aspartate (Wmol (g wet wt.)31) 0.9 þ 0.1 0.6 þ 0.2 0.3 þ 0.1 0.4 þ 0.1
FEa 0.43 þ 0.04 0.35 þ 0.04 0.39 þ 0.01 0.38 þ 0.01
KT (Wmol (g wet wt.)31 min31) 0.79 þ 0.21 1.8 þ 0.2 1.9 þ 0.22 0.77 þ 0.2
XTCA (Wmol (g wet wt.)31 min31) 0.93 þ 0.21 1.8 þ 0.2 1.9 þ 0.22 1.1 þ 0.2
vt50, di¡erence in time for half-maximal enrichment of glutamate C4 and C2; FEa, fractional enrichment of acetyl-CoA; KT, total
Krebs cycle £ux parameter; XTCA, total Krebs cycle £ux. All values are expressed as mean þ S.E.M.
Signi¢cance: 1normoxic vs. PC postischemic, P6 0.05; 2I20 vs. PCI20, P6 0.05.
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The 13C-spectra of glutamate and the 1H-spectra
of alanine are mutually subsidiary: 13C-enrichment
in alanine generally correlates with the corresponding
enrichment of acetyl-CoA [30,31]. As shown in Table
1, the 13C-enrichment of alanine re£ects the enrich-
ment of [2-13C]acetyl-CoA under both normoxic and
ischemic conditions [32]. This did not occur in the
PCI hearts after reperfusion (set 2, E): the alanine
enrichment was 17%, and that of acetyl-CoA was
35%. The signi¢cant decrease in alanine enrichment
(E vs. D and A; P6 0.005) after 30 min reperfusion
points to an incomplete recovery of alanine transa-
minase activity. Lactate enrichment was similar in all
except the ischemic preconditioned group (D), in
which it was lower (P6 0.05) than in the normoxic
(A) and ischemic (B) groups.
The less severe protocol of 20 min ischemia and
30 min reperfusion showed almost identical 13C-en-
richment of alanine and acetyl-CoA in groups PCI20
and I20, similar to those obtained from the normoxic
group A (Table 1).
4. Discussion
4.1. Preconditioning is not due to acidosis
Reduced acidosis has been associated with protec-
tive preconditioning e¡ects by many authors [5^7,33^
35]. However, Schaefer et al. [36], Soares et al. [11]
and Chen et al. [37] indicated that in preconditioned
rat hearts pH during ischemia is unrelated to func-
tional recovery. Cave and Garlick [38] showed that
attenuation of acidosis is not a prerequisite for pre-
conditioning. Our model [16] does not produce
acidosis during preconditioning nor reduces acidosis
during ischemia in PCI hearts, but improves enzyme
release and functional recovery. We therefore pro-
vide evidence that there is no relationship between
the protection exerted by preconditioning and re-
duced acidosis during ischemia, in line with Harrison
et al. [39] who showed that their PC protocol (5 min
ischemia and 10 min reperfusion) also failed to mod-
ify acidosis during ischemia.
4.2. Preconditioning a¡ects early glycogen use
It has been clearly demonstrated that, in glucose/
insulin perfused hearts, all of the glucose residues in
the macromolecule make a uniform contribution to
the 13C NMR signal of glycogen [40^42]. The syn-
thesis and breakdown of glycogen have a mainly
ordered molecular pattern, with the glucose residues
that are incorporated last being released ¢rst
[4,43,44]. Our data concerning glycogen labeling
and synthesis (Fig. 8) are in agreement with those
reported by Laughlin et al. [45] for the same time
window.
We did not choose the glycogen-depleted heart
model in order to avoid the possibility that this treat-
ment might produce a sort of ‘metabolic hibernation’
or a faster glycogenolysis [46,47]. In the PCI group,
the ¢rst 2 min ischemia produced a 24% decrease in
labeled glycogen, and the subsequent 3 min reperfu-
sion did not increase glycogen content (data not
shown); a 30% decrease in glycogen was observed
after 5 min (Fig. 8). This ¢nding is in agreement
with that of Kalil-Filho et al. [48], who found sig-
ni¢cant but transient glycogenolysis during early re-
perfusion. According to Jeremy et al. [49], glycoge-
nolysis may be related to the functional recovery of
postischemic myocardium, which requires glycolysis
during early reperfusion, in order to allow glycolyti-
cally derived ATP to support such membrane activ-
ities as ion pumping. In our experiments, the subse-
quent ischemia^reperfusion cycles did not produce
any appreciable variations in glycogen, which may
be reasonably considered to be due to a similar
rate of glycogen synthesis and breakdown.
The amount of total (labeled and unlabeled) gly-
cogen measured after the initial 30 min perfusion
period was 17.2 Wmol/g; its labeled fraction was 5.1
Wmol/g, corresponding to 25^30%. The mean 24%
decrease in labeled glycogen observed after precondi-
tioning (1.6 Wmol/g, very similar to the 1.8 Wmol/g
derived from independent biochemical determina-
tions of total glycogen) therefore only represents a
V10% variation in total glycogen. This agrees with
our observation that preconditioning does not pro-
duce any signi¢cant variation in intracellular pH dur-
ing the short ischemia-reperfusion cycles. The 10%
di¡erence in total glycogen at the onset of the long
ischemic period between PCI and I hearts cannot
justify the cardioprotective e¡ects of preconditioning.
Asimakis [50] recently reached the same conclusion
when he retrospectively examined his published data
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(see also [11]). Preconditioning is more likely to a¡ect
glycogen use during long ischemia; glycogen was im-
mediately used in group I, but remained almost con-
stant for up to 5^8 min in PCI hearts. Later, the
glycogen stores in the two groups were depleted at
comparable rate. Overall, these results indicate that
glycogenolysis is slower during early ischemia in PCI
hearts, in line with the results already published
[4,51]. Interestingly, pretreatment with adenosine (a
popular candidate as the mediator of precondition-
ing) may also delay ischemic glycogen depletion [52].
Preliminary results from our group indicate that 2-
chloro-N6-cyclopentyladenosine (CCPA), a selective
adenosine A1 receptor agonist, mimics ischemic pre-
conditioning in rat hearts by delaying and reducing
glycogenolysis [53] to the same extent as precondi-
tioning, whereas a selective adenosine A1 receptor
antagonist, 8-(p-sulfophenyl)theophylline (8-SPT),
greatly reduces the preconditioning e¡ect on glyco-
genolysis.
The relationship between slow (or delayed) glyco-
gen use and the recovery of contractile function is
still a matter of debate, and the present results can-
not provide any de¢nite answer. However, in support
of the view that a strict relationship exists between
the two parameters, our study does show that the
glycogen stores are partially depleted in PCI hearts,
but almost completely depleted in I organs after
30 min ischemia. This parallels the contractile recov-
ery and viability of myocardial cells, as shown by the
behavior of enzymatic markers; our data are in
agreement with those of Cross et al. [54], who indi-
cated that di¡erences in the extent of glycogen deple-
tion during ischemia may be responsible for the dif-
ferences in recovery. In our experiments, only PCI
hearts recovered metabolic and functional activity
on reperfusion, with labeled glycogen levels returning
to up to 27% of their baseline values (Fig. 8). We
observed a transient glycogenolysis during early re-
perfusion before glycogen synthesis. Altogether, the
average postischemic labeling rate was four times
slower than the average initial labeling rate, whereas
the I hearts showed virtually no synthetic activity
[48]. Glycogen synthesis is known to be regulated
by the activity of the enzyme glycogen synthase
that exists primarily in the multiple-phosphorylated
physiologically inactive glycogen synthase D (GS D)
form. Laughlin et al. [55] demonstrated that the ac-
tivity of GS I (the physiologically active, glucose 6-
phosphate independent form of the enzyme) is likely
to be the rate-limiting step for glycogen synthesis in
the heart with little in£uence of the allosteric regu-
lators (Pi, ATP, UTP, and Mg2). Therefore, we at-
tribute the low glycogen postischemic synthesis, also
observed by Finegan et al. [56] in di¡erent experi-
mental conditions, to depressed activity of glycogen
synthase GS I.
4.3. Restoration of energy production
Intracellular glucose, after phosphorylation, is
used for glycogen synthesis, ribose synthesis, and
broken down to pyruvate throughout the glycolytic
pathway. Pyruvate enters the Krebs cycle mainly oxi-
dized to acetyl-CoA by the pyruvate dehydrogenase
complex (PDC), but also carboxylated to oxaloace-
tate by pyruvate carboxylase or malic enzyme: this
second mechanism is termed anaplerosis. Both the
oxidative and the anaplerotic mechanisms are active
under normoxic conditions, the latter allowing a par-
tial supply of Krebs cycle intermediates and a recy-
cling of CO2 derived from the action of dehydrogen-
ases. During stop-£ow ischemia glycolysis is
inhibited, glucose uptake interrupted, and glycolytic
£ux supported by glycogen breakdown. Then, all of
the metabolic end products accumulate in the cytosol
with depletion of Krebs cycle intermediates [57]. On
reperfusion, the Krebs cycle is replenished by resto-
ration of the oxidative metabolism and anaplerotic
reactions [57,58].
Anaplerosis has previously been characterized in
cases where energy demand is increased by an in-
crease in workload or, less commonly, where energy
supply is decreased by a decrease in blood £ow. Rus-
sell and Taegtmeyer [59] validated the importance of
anaplerosis to maintain of stable contractile perfor-
mance, and Jessen et al. [60] reported a linear rela-
tionship between anaplerosis and mechanical func-
tion. Taegtmeyer and de Villalobos [61] have shown
that, also in clinical practice, the replenishment of
the depleted TCA cycle through anaplerosis is one
of the prerequisites for a return to normal contractile
function.
In order to investigate the relationship between
substrate oxidation and the restoration of energy
production in PCI and I hearts, we analyzed gluta-
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mate 13C-isotopomers from heart extract. This pro-
vides a measurement of the relative activity of
anaplerotic and oxidative reactions. In fact, [1-13C]
glucose metabolism through glycolysis to the level
of pyruvate results in the observable label of
[3-13C]alanine and [3-13C]lactate but not of pyruvate
because the latter is present in quantities too small to
be NMR detectable. Krebs cycle oxidation of
[1-13C]glucose produces glutamate 13C-isotopomers,
present in high enough concentration to be NMR
detectable. Glutamate is in rapid equilibration, via
transamination, with the Krebs cycle intermediate
K-keto-glutarate.
Our data from the normoxic group (set 2: A) are
comparable with those reported in the literature
under similar perfusion conditions. The exogenous
glucose contribution to acetyl-CoA entering the
TCA cycle is V86%, thus con¢rming that the glyco-
lytic pathway is completely activated. The anapler-
otic £ux is relatively low in the absence of exogenous
fatty acids and the presence of insulin, and the total
Krebs cycle £ux empirically estimated is 0.93 þ 0.2
Wmol (g wet wt)31 min31. In agreement with the ¢nd-
ings of Chatman and Forder [62] and Zhao et al.
[32], who used glucose in a non-recirculating perfu-
sion, we found good agreement between alanine and
acetyl-CoA 13C-enrichment.
As a result of 30 min of ischemia (set 2: B and D),
the contribution of endogenous substrates to Krebs
cycle activity is slightly greater in PCI than in I
organs. The fact that the 13C-fractional enrichment
of alanine is greater than the enrichment of [2-13C]-
acetyl-CoA in PCI organs (set 2: D) may indicate
increased transaminase activity due to the purine re-
lease produced by the preconditioning period [63].
The status reached by PCI hearts after 30 min
reperfusion (set 2: E) is very di¡erent from that ob-
served initially, and thus proves the incomplete re-
covery. The total Krebs cycle £ux is signi¢cantly
higher than the normoxic one (1.8 þ 0.2 Wmol (g
wet wt.)31 min31, P6 0.05). The exogenous glucose
contribution to the oxidative £ux is lower (70 vs.
86%), anaplerosis is particularly high (23 þ 4 vs.
11 þ 3%; P6 0.05), with the £ux through pyruvate
carboxylase as high as 80% (under our experimental
conditions, this was the major pathway for labeling
the anaplerotic substrate). The substantial di¡erence
between alanine and acetyl-CoA enrichment (17 þ 2.6
vs. 35 þ 4%, P6 0.05) con¢rms the picture of glucose
metabolism shifted to the replenishment of the de-
pleted Krebs cycle. These data are physiologically
relevant considering the highly increased Krebs cycle
£ux in the preconditioned postischemic myocardium
(Table 2). Increased Krebs cycle £ux probably re-
£ects increased contractile or non-contractile (e.g.,
calcium handling) energy demands in reperfused
hearts. A number of studies indicate that oxygen
consumption is increased in the postischemic reper-
fused myocardium [64]. Because oxygen consumption
is related to total Krebs cycle activity, our results ^
an increased total Krebs cycle £ux in the precondi-
tioned postischemic myocardium ^ are consistent
with the recovery of the PCI group, in accord with
Weiss et al. [21]. Evaluating the e¡ects of amino
acids on substrate selection after 30 min no-£ow is-
chemia and 30 min reperfusion, Jessen et al. [60]
reported percent values of anaplerosis similar to
ours. Although their perfusion conditions (lactate,
acetate, and glucose as substrates) were very di¡erent
from ours, our values of anaplerosis and functional
recovery ¢t the strict relationship between the varia-
bles shown in that paper.
Thirty minutes of ischemia irreversibly damaged
the untreated controls (set 2: C), preventing the col-
lection of suitable data on anaplerosis and 13C-en-
richment of alanine, lactate, and acetyl-CoA after
reperfusion. Therefore, we performed additional ex-
periments and shortened the ischemic stress to 20
min ischemia. Both ischemic controls and precondi-
tioned hearts recovered function, but anaplerosis was
found to be signi¢cantly higher in the former (39 þ 9
vs. 13 þ 3%, P6 0.05) with the £ux through pyruvate
carboxylase close to 70%, while alanine, lactate and
acetyl-CoA 13C-enrichment were similar in both
groups. The high anaplerosis of I20 was in agreement
with the high TCA cycle £ux (1.9 þ 0.2 Wmol (g wet
wt.)31 min31) and the lower recovery in contractility.
Instead, TCA cycle £ux, anaplerosis and labeling of
the anaplerotic pool of the preconditioned group
PCI20 were similar to that of the normoxic control
(Table 2: A and [15]): the overall picture indicates
that the PCI20 group recovered completely preische-
mic conditions.The results can be summarized as fol-
lows.
b In the case of 30 min ischemia and 30 min reper-
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fusion, the absolute rate of the postischemic TCA
cycle of preconditioned hearts is higher than the
preischemic one. Nevertheless the PDC activity is
lower than before ischemia: acetyl-CoA 13C-label-
ing is 70% instead of 86%. Therefore, the rebuild-
ing and rebalancing of the intermediatory metab-
olism is granted by the higher participation of the
anaplerotic mechanisms (mainly through pyruvate
carboxylase) in providing intermediates. The ische-
mic controls did not recover.
b After 20 min ischemia and 30 min reperfusion, the
preconditioned group shows preischemic values
(% labeling of acetyl-CoA, absolute rate of the
postischemic TCA cycle and anaplerosis) compa-
rable to the normoxic situation. Di¡erently, the
ischemic control group shows a signi¢cant high
rate of the TCA cycle and active anaplerotic mech-
anisms.
There is no contradiction in the results of the two
experiments characterizing at a speci¢c ¢xed time
(30 min reperfusion after ischemia, steady state con-
ditions) di¡erent moments of the recovery of TCA
cycle activity because the closer the status to the pre-
ischemic one, the lower TCA cycle £ux and anaplero-
sis will be.
In both experiments we have indications that our
protocol of PC promotes a better restoration of
Krebs cycle £ux toward preischemic conditions. In
fact, PC allows a partial recovery of glucose metab-
olism in the case of severe ischemia, and a full re-
covery in the case of mild ischemia while in the con-
trol groups respectively there was either a total lack
of recovery, or only a partial one. Our model of
preconditioning does not produce di¡erences in
harmful metabolic end products (H and lactate)
or preischemic glycogen stores; therefore, we specu-
late that the better restoration can be linked to the
delayed glycogen utilization with concomitant glu-
cose uptake, attributed by Weiss et al. [4] to the
glucose transporter activation due to precondition-
ing. Also King and Opie [65] indicate that PC in-
creases glucose uptake possibly by increasing mem-
brane transporter density. A better postischemic
substrate (glucose) availability could allow a more
e⁄cient glycolysis (thus decreasing cytosolic Ca2
accumulation), with a better ‘refeeding’ of TCA cycle
intermediates through anaplerotic reactions and a
faster PDC activation [58]. We believe that the better
restoration of TCA cycle £ux can be a general phe-
nomenon of PC in glucose perfused heart.
4.4. Limitations
A possible limitation of this model is that only
glucose has been used in the perfusion medium, in
analogy with many papers [6,11,33^35]. In vivo the
heart largely relies on free fatty acids with preferen-
tial use of glucose during ischemia. We do not know
whether a more complete perfusion medium would
change our results. It is known that fatty acids mod-
ulate glycolysis [56]. Nevertheless, the e¡ects pro-
duced by PC on glycogen use reported by Jennings
et al. [51] and Wolfe et al. [5] are analogous to those
found in our experiments.
Limitations of a [1-13C]glucose perfusion are
mostly due to the 50% dilution of labeled acetyl-
CoA units combined with the relatively small gluta-
mate pool. The glutamate and the aspartate pools
account for 96^97% of the sum total of all Krebs
cycle derived pools in glucose perfused hearts and
were quanti¢ed from the NMR spectra of the ex-
tracts. Changes in the smaller pools (oxaloacetate,
fumarate, malate: 3^4% of the sum total of all Krebs
cycle derived pools) have negligible impact on the
experimentally calculated Krebs cycle £ux.
5. Conclusions
In summary, we show that the protective e¡ects of
preconditioning are associated with a reduction in
glycogenolysis early during ischemia. However, our
data indicate that this protection does not imply ma-
jor variations in intracellular pH and is independent
of preischemic glycogen levels. We report an associ-
ation with active anaplerosis during reperfusion, in-
dicating that preconditioning improves metabolism
during this period by facilitating the restoration of
glucose metabolism.
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